UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

September 10, 2019

 

001-36686

(Commission file number)

 

Forward Pharma A/S

(Translation of registrant’s name into English)

 

 

Østergade 24A, 1st Floor

1100 Copenhagen K, Denmark

(Address of principal executive office)

 

________________________________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F [ X ] Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes [  ] No [ X ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes [  ] No [ X ]

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [  ] No [ X ]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

 

 

 

 

Item 1. Other Items

 

Forward Pharma A/S (the “Company”) is submitting this Report on Form 6-K to provide its (i) interim condensed consolidated statement of financial position as of June 30, 2019, unaudited, and December 31, 2018 and (ii) unaudited interim condensed consolidated statements of profit or loss each of the six-month periods ended June 30, 2019 and 2018, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. Exhibits 99.1 and 99.2 are furnished herewith solely for the purpose of meeting the requirements of Nasdaq Stock Market Rule 5250(c)(2) to submit an interim balance sheet and income statement as of the end of the Company’s second quarter.

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

 

99.1*

Interim condensed consolidated statement of Financial Position of the Company as of June 30, 2019, unaudited, and December 31, 2018

 

99.2*

Unaudited interim condensed consolidated statement of Profit or Loss of the Company for each of the six-month periods ended June 30, 2019 and 2018

 

*

Furnished herewith solely for the purpose of meeting the requirements under Nasdaq Stock Market Rule 5250(c)(2) in connection with submission of an interim balance sheet and income statement as of the end of its second quarter.

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Date:  September 10, 2019	Forward Pharma A/S
	By:	/s/ Claus Bo Svendsen
		Name:  Claus Bo Svendsen
		Title:    Chief Executive Officer

 

 

 

 

 

 

3

Exhibit 99.1

 

 

Interim Condensed Consolidated Statement of Financial Position

 

as of June 30, 2019, Unaudited, and December 31, 2018

 

Assets

		June 30, 2019 (Unaudited)				December 31, 2018
		USD `000				USD `000
Non-current Assets:
Other non-current assets			2				2
Total non-current assets			2				2
Prepaid expenses			168				340
Other receivables			153				266
Income tax receivable			181				182
Cash and cash equivalents			80,169				82,542
Total current assets			80,671				83,330
Total assets			80,673				83,332

 

Shareholders’ Equity and Liabilities

 

		June 30, 2019 (Unaudited)				December 31, 2018
		USD `000				USD `000
Share capital			152				152
Other components of equity:
Foreign currency translation reserve			87,253				87,748
Accumulated deficit			(7,397	)			(5,686	)
Equity attributable to shareholders of the Parent			80,008				82,214
Total shareholders’ equity			80,008				82,214
Trade payables			207				428
Income tax payable			—				68
Accrued liabilities			458				622
Total current liabilities			665				1,118
Total shareholders’ equity and liabilities			80,673				83,332

 

 

 

4

Exhibit 99.2

 

 

Unaudited Interim Condensed Consolidated Statement of Profit or Loss

 

for the six-month periods ended June 30, 2019 and 2018

 

amounts in thousands except per share amounts

 

 

		Six-Month Periods Ended June 30,
		2019				2018
		USD				USD
Research and development costs			(626	)			(1,843	)
General and administrative costs			(2,602	)			(5,803	)
Operating loss			(3,228	)			(7,646	)
Foreign exchange rate gain			187				1,859
Other finance income			191				313
Loss before taxes			(2,850	)			(5,474	)
Income tax benefit			—				204
Net loss for the period			(2,850	)			(5,270	)
Net loss for the period attributable to:
Equity holders of the Parent			(2,850	)			(5,270	)
Per share amounts:
Net loss per share basic and diluted			(0.03	)			(0.06	)

 

 

 

 

 

 

5